MedTrace Logo

Study on Sotrovimab and Its Impact on the Immune Response to COVID-19 Infection in Real-life in the UAE and Bahrain

NCT05398718 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20000

Last updated 2022-06-01

No results posted yet for this study

Summary

The United Arab Emirates (UAE), the Kingdom of Bahrain, Kuwait, Oman, and Qatar have authorised sotrovimab for emergency use. Local experience among physicians include recent successful COVID-19 vaccine pivotal studies supported by the authorities' willingness to expedite understanding of the role of monoclonal antibodies such as sotrovimab in the management of COVID-19 and expertise to integrate the latest knowledge into the local or regional COVID-19 management guidelines. The aim of this study is to collect local clinical evidence for sotrovimab effect in the real-life setting in the UAE and the Kingdom of Bahrain. Overall study population is 20,000 and the duration of the study will be approximately six months from recruitment date.

Conditions

Interventions

DRUG

Sotrovimab

collect local clinical evidence for sotrovimab effect in the real-life setting

Sponsors & Collaborators

  • Abu Dhabi Health Services Company

    lead OTHER_GOV

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-12
Primary Completion
2022-12-15
Completion
2022-12-31

Countries

  • Bahrain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05398718 on ClinicalTrials.gov